NEW: Examine Personalized — easily keep up with the latest research. On sale until tonight! Learn more

Studies related to Pain and Serrapeptase

Evaluation Of Serratia Peptidase In Acute Or Chronic Inflammation Of Otorhinolaryngology Pathology: A Multicentre, Double-blind, Randomized Trial Versus Placebo

Effect Decrease
Trial Design Double blind
Trial Length 1-2 Weeks
Number of Subjects 193
Sex Both Genders
Age Range 18-29, 30-44, 45-64, 65+
Notes for this study:
In persons with acute or chronic ear, nose or throat disorders given 10mg of serrapeptase thrice daily (30mg total), supplementation was more effective than placebo in reducing abnormalities of mucus production and swallowing and was also analgesic.

Full details on all 5 studies are available to Examine Plus members.

Already a member? Login now to access.